BioCardia (BCDA) executive compensation, 2025 proxy

Peter Altman, Ph.D., President, Chief Executive Officer, and Director, was paid $493,388 in fiscal 2024, down 43% from $862,836 the year before.

Open BCDA in Gloom →
BioCardia's chart, financials and news, free in your browser.Open BCDA in Gloom →
Filed
November 3, 2025
Annual meeting
December 2, 2025
Pay year
fiscal 2024
Named executives
3
CEO total pay
$493,388-43% vs prior year
CEO current salary
$531,000
CEO target bonus
50% of base salary
CEO compensation actually paid
$423,4762024 pay-versus-performance table
Average non-PEO NEO pay
$303,3732024 Summary Compensation Table
Company net loss
$7,946 thousand2024 pay-versus-performance table
CEO change-in-control salary
150%Severance payment percentage

How Ph.D. was paid

$493,388 in total for fiscal 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary100%

Named executive officers

ExecutiveTotal
Peter Altman, Ph.D.President, Chief Executive Officer, and Director$493,388
David McClungChief Financial Officer$354,942
Edward GillisSenior Vice President, Devices$251,804

What changed and why

  • $493K$493,388: CEO total compensation in 2024, down from $862,836 in 2023.
  • $423K$423,476: CEO compensation actually paid in 2024, compared with $600,059 in 2023.
  • 50%$531,000: CEO’s current annual base salary, with a target annual bonus equal to 50% of base salary.
  • $0$0: Stock and option awards reported for all named executives in 2024.
  • $303K$303,373: Average 2024 Summary Compensation Table total for non-PEO named executives.
  • No stock options were issued to executive officers during 2024.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.